Management of toenail onychomycosis

American Journal of Health-System Pharmacy

Volumn 56, Issue 9, 1999, Pages 865-871

  Tom, Catherine M ^a   Kane, Michael P ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antifungals; Clinical studies; Diagnosis; Drug administration routes; Drugs; Economics; Itraconazole; Onychomycosis; Surgery; Terbinafine hydrochloride; Topical preparations

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIAZEPAM; DIGOXIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; ISONIAZID; ITRACONAZOLE; METHYLPREDNISOLONE; MEVINOLIN; MIDAZOLAM; PHENYTOIN; PLACEBO; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; TERBINAFINE; TERFENADINE; TRIAZOLAM; WARFARIN;

CANDIDA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; FEMALE; FLATULENCE; GASTRITIS; HEADACHE; HUMAN; MALE; NAIL DISEASE; ONCHOCERCIASIS; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RHINITIS; SINUSITIS; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; VISUAL DISORDER;

EID: 0033135837     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.9.865     Document Type: Review

References (35)

1. Gupta AK, Shear NH. Onychomycosis: going for cure. Can Fam Physician. 1997; 43:299-305.
2. Daniel CR. The diagnosis of nail fungal infection. Arch Dermatol. 1991; 127:1566-7.
3. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol. 1996; 35:S2-5.
4. Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol. 1994; 31:S74-7.
5. Midgley G, Moore MK, Cook JC et al. Mycology of nail disorders. J Am Acad Dermatol. 1994; 31:S68-74.
6. Elewski BE. Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol. 1996; 35:S6-9.
7. Zaias N. Clinical manifestations of onychomycosis. Clin Exp Dermatol. 1992; 17:6.
8. Zaias N, Glick B, Rebell G. Diagnosing and treating onychomycosis. J Fam Pract. 1996; 42:513-8.
9. Rich P. Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol. 1996; 35:S10-2.
10. Lugo-Somolinos A, Sanchez JL. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol. 1992; 26:408-10.
11. Lubeck DP, Patrick DL, McNulty P et al. Quality of life of persons with onychomycosis. Qual Life Res. 1993; 2:341-8.
12. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9.
13. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol. 1996; 35:S26-30.
14. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36:S3-8.
15. Sporanox package insert. Titusville, NJ: Janssen Pharmaceutica; 1996.
16. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996; 51(4):585-620.
17. Bennett JE. Antimicrobial agents: antifungal agents. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hlll; 1997:1175-90.
18. Lamisil package insert. East Hanover, NJ: Novartis Pharmaceutical; 1997.
19. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol. 1992; 126(suppl 39):28-32.
20. Scher RK, Breneman D, Rich P et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998; 38:S77-86.
21. Ling MR, Swinyer LJ, Jarratt MT et al. Once-weekly fluconazole (450 mg) for 4, 6 or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998; 38:S95-102.
22. Willemsen M, DeDoncker P, Willems J et al. Post-treatment itraconazole levels In the nail: new implications for treatment in onychomycosis. J Am Acad Dermatol. 1992; 26:731-5.
23. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment of onychomycoses. Br J Dermatol. 1990; 123:481-6.
24. Jones HE, Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol. 1996; 35:589-90.
25. Svejgaard EL, Brandrup F, Kragballe K et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh). 1997; 77:66-9.
26. Watson A, Marley J, Ellis D et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995; 33:775-9.
27. Havu V, Brandt H, Heikkila H et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol. 1997; 136:230-4.
28. DeDoncker P, Decroix J, Pierard GE et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996; 132:34-41.
29. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol, 1996; 23:259-62.
30. DeBacker M, DeKeyser P, DeVroey C et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol. 1996; 134(suppl 46):16-7.
31. Arenas R, Dominguez-Cherit J, Fernandez LMA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995; 34:138-43.
32. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996; 34:595-600.
33. Marchetti A, Piech CT, McGhan WF et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther. 1996; 18:757-77.
34. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government prospective. Br J Dermatol. 1994; 130(suppl 43):32-4.
35. Arikian SR, Einarson TR, Kobelt-Nguyen G et al. The Onychomycosis Study Group. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol. 1994; 130(suppl 43):35-44.